BioPharma Dive 2026-01-14 JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view
BioPharma Dive 2026-01-12 JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
BioPharma Dive 2026-01-12 AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
BioPharma Dive 2026-01-12 Best practices for COA selection: Building a stronger foundation for clinical trials